The document discusses the current state and expected growth trends of the in vitro diagnostics (IVD) market. It notes that the global IVD market was estimated at $54.2 billion in 2013 and is expected to grow 4% annually to $64.3 billion by 2018. Technological advances in areas like genomics, bioinformatics, and miniaturization have transformed diagnostic laboratory technology in recent years. Personalized medicine, infectious disease testing, and other applications are driving growth in the IVD market. However, economic instability, rising healthcare costs, and reimbursement changes pose challenges for the industry.
Molecular diagnostics market & forecast (by application, technology, countrie...Renub Research
Renub Research (http://renub.com/report/molecular-diagnostics-market-forecast-by-application-technology-countries-companies-clinical-trials-to-2017-global-analysis-114) has announced the addition of the "Molecular Diagnostics Market & Forecast (By Application, Technology, Countries, Companies & Clinical Trials) to 2017: Global Analysis" report to its offering
Molecular diagnostics market & forecast (by application, technology, countrie...Renub Research
Renub Research (http://renub.com/report/molecular-diagnostics-market-forecast-by-application-technology-countries-companies-clinical-trials-to-2017-global-analysis-114) has announced the addition of the "Molecular Diagnostics Market & Forecast (By Application, Technology, Countries, Companies & Clinical Trials) to 2017: Global Analysis" report to its offering
5 Trends to Watch in the Medical Device Industry in 2016Mercer Capital
Demographic shifts underlie the long-term market opportunity for medical device manufacturers. While efforts to control costs on the part of the government insurer in the U.S. may limit future pricing growth for incumbent products, a growing global market provides domestic device manufacturers with an opportunity to broaden and diversify their geographic revenue base. Developing new products and procedures is risky and usually more resource intensive compared to some other growth sectors of the economy. However, barriers to entry in the form of existing regulations provide a measure of relief from competition, especially for newly developed products.
Mercer Capital's Value Focus: Medical Device Manufacturers | Q4 2016 | Pfizer...Mercer Capital
Mercer Capital provides medical device manufacturers, related start-up enterprises, and private equity funds with valuation services, including purchase price allocation, 409a compliance, goodwill impairment testing, and other transaction and valuation advisory services.
Each issue includes a segment focus, market overview, mergers and acquisitions review, and more.
Immuno-oncology, also called as cancer immunotherapy is a biologic treatment, which enhances the body’s natural defenses to stop the growth of cancer. This therapy uses constituents made by the body or in a research laboratory to improve or reestablish the immune system function.
Genome Editing Market Analysis By Technology (CRISPR, TALEN, ZFN), By Delivery Method (Ex-vivo, In-vivo), By Application (Animal/Plant Cell Editing), By Service (In-house, Outsourced), By End-use And Segment Forecasts, 2018 - 2025
The global liquid biopsy market is projected to reach $12,933 million by 2030 and grow with a significant CAGR of 15.87%
get more detailed : https://bisresearch.com/industry-report/global-liquid-biopsy-market.html
Cancer immunotherapies from the perspectives of oncology nursesZeena Nackerdien
This presentation, tailored for oncology nurses, provides an overview of immunotherapy classes, how they work, and how key side effects are typically managed. (Disclaimer: Content is based on peer-reviewed literature; however, it is not a substitute for medical advice. Please consult your doctor)
Regenerative Medicine Industry Outlook 2014Pete Shuster
This is an excellent presentation on companies and products that are making their mark on the Regenerative Medicine Market. The outlook for 2014 is encouraging.
New technologies and the outsourcing of clinical trials to lower-cost countries will slow the recent annual increases in expenditures in the U.S. to a 3.3% compound annual growth rate (CAGR) over the forecast period.
Telemedicine Market size was valued at USD 24.9 billion in 2016 and is anticipated to reach USD 113.1 billion by 2025, with a CAGR of 18.3%. Global telemedicine demand is expected to show a steady growth on account of increasing focus on emergency healthcare services
United States IVD Market (By Application Segments, Products, Region, End User...iGATE RESEARCH
iGATE Research has released a research report on “United States IVD Market (By Application Segments, Products, Region, End Users) Size, Share, Major Deals & Company Analysis - Forecast to 2025”
Click here to view the complete report: http://igateresearch.com/FullReportDetail.php?p=166
Contact US
iGATE Research PVT LTD
Ravi Sinha
Sales Manager
Marketing and Sales Divison
Email: ravi.sinha@igateresearch.com
Contact: +91-858-684-0791, +91-821-092-7469 (INDIA)
Web: www.igateresearch.com
Biomarkers are novel diagnostic tools that provide intelligence to physician about disease progression and treatment effects. Advancement in understanding of human genome promotes its application in diagnosis of disease on molecular basis. Biomarker technology is evidencing increased application in disease diagnosis, drug development and formulation, diagnosis for exposure of certain harmful chemical and prognostic treatments.
M&A activity in 2014 was dynamic, with more in vitro diagnostics (IVD) transactions compared to the previous two years combined. For 2015 to date, Worldwide IVD transactions (including instrument/reagent manufacturers, genome informatics and reference labs) are on par with 2014 activity although there has been a sharp decline in acquisitions in China. Also, EY’s Medtech Firepower Index shows steady growth in “firepower” – which EY defines as a company’s ability to do M&A based on the strength of its balance sheet -- since 2011, indicating high borrowing capacity and the potential for future transaction execution. In particular, the diagnostics market has seen an emergence of creative deal making between nontraditional partners specifically within oncology, NIPT and MRSA.
5 Trends to Watch in the Medical Device Industry in 2016Mercer Capital
Demographic shifts underlie the long-term market opportunity for medical device manufacturers. While efforts to control costs on the part of the government insurer in the U.S. may limit future pricing growth for incumbent products, a growing global market provides domestic device manufacturers with an opportunity to broaden and diversify their geographic revenue base. Developing new products and procedures is risky and usually more resource intensive compared to some other growth sectors of the economy. However, barriers to entry in the form of existing regulations provide a measure of relief from competition, especially for newly developed products.
Mercer Capital's Value Focus: Medical Device Manufacturers | Q4 2016 | Pfizer...Mercer Capital
Mercer Capital provides medical device manufacturers, related start-up enterprises, and private equity funds with valuation services, including purchase price allocation, 409a compliance, goodwill impairment testing, and other transaction and valuation advisory services.
Each issue includes a segment focus, market overview, mergers and acquisitions review, and more.
Immuno-oncology, also called as cancer immunotherapy is a biologic treatment, which enhances the body’s natural defenses to stop the growth of cancer. This therapy uses constituents made by the body or in a research laboratory to improve or reestablish the immune system function.
Genome Editing Market Analysis By Technology (CRISPR, TALEN, ZFN), By Delivery Method (Ex-vivo, In-vivo), By Application (Animal/Plant Cell Editing), By Service (In-house, Outsourced), By End-use And Segment Forecasts, 2018 - 2025
The global liquid biopsy market is projected to reach $12,933 million by 2030 and grow with a significant CAGR of 15.87%
get more detailed : https://bisresearch.com/industry-report/global-liquid-biopsy-market.html
Cancer immunotherapies from the perspectives of oncology nursesZeena Nackerdien
This presentation, tailored for oncology nurses, provides an overview of immunotherapy classes, how they work, and how key side effects are typically managed. (Disclaimer: Content is based on peer-reviewed literature; however, it is not a substitute for medical advice. Please consult your doctor)
Regenerative Medicine Industry Outlook 2014Pete Shuster
This is an excellent presentation on companies and products that are making their mark on the Regenerative Medicine Market. The outlook for 2014 is encouraging.
New technologies and the outsourcing of clinical trials to lower-cost countries will slow the recent annual increases in expenditures in the U.S. to a 3.3% compound annual growth rate (CAGR) over the forecast period.
Telemedicine Market size was valued at USD 24.9 billion in 2016 and is anticipated to reach USD 113.1 billion by 2025, with a CAGR of 18.3%. Global telemedicine demand is expected to show a steady growth on account of increasing focus on emergency healthcare services
United States IVD Market (By Application Segments, Products, Region, End User...iGATE RESEARCH
iGATE Research has released a research report on “United States IVD Market (By Application Segments, Products, Region, End Users) Size, Share, Major Deals & Company Analysis - Forecast to 2025”
Click here to view the complete report: http://igateresearch.com/FullReportDetail.php?p=166
Contact US
iGATE Research PVT LTD
Ravi Sinha
Sales Manager
Marketing and Sales Divison
Email: ravi.sinha@igateresearch.com
Contact: +91-858-684-0791, +91-821-092-7469 (INDIA)
Web: www.igateresearch.com
Biomarkers are novel diagnostic tools that provide intelligence to physician about disease progression and treatment effects. Advancement in understanding of human genome promotes its application in diagnosis of disease on molecular basis. Biomarker technology is evidencing increased application in disease diagnosis, drug development and formulation, diagnosis for exposure of certain harmful chemical and prognostic treatments.
M&A activity in 2014 was dynamic, with more in vitro diagnostics (IVD) transactions compared to the previous two years combined. For 2015 to date, Worldwide IVD transactions (including instrument/reagent manufacturers, genome informatics and reference labs) are on par with 2014 activity although there has been a sharp decline in acquisitions in China. Also, EY’s Medtech Firepower Index shows steady growth in “firepower” – which EY defines as a company’s ability to do M&A based on the strength of its balance sheet -- since 2011, indicating high borrowing capacity and the potential for future transaction execution. In particular, the diagnostics market has seen an emergence of creative deal making between nontraditional partners specifically within oncology, NIPT and MRSA.
SCLERODERMA: Searching for the Cause and the Cure
Maureen D. Mayes, MD, MPH Professor of Medicine Director of the Scleroderma Program Division of Rheumatology University of Texas - Houston
Presented at the Scleroderma Patient Education Conference, Saturday, October 19, 2013 at Northwestern Memorial Hospital.
Hosted by the Scleroderma Foundation, Greater Chicago Chapter and the Northwestern Scleroderma Program.
How to build your perfect elevator pitch?Geert Houben
Are you able to explain your company or idea in a very short time?
This presentation contains a concrete step-by-step building plan for your perfect 'elevator pitch'.
It's made after Geert Houben's experiences at the BlackBox Connect bootcamp in 2015, powered by Google For Entrepreneurs.
5 Cutting-Edge Trends in Molecular DiagnosticsBruce Carlson
Despite the focus on novelty in this field, it is near 2 decades old. Yet a lot is changing. A look at a few trends that could change molecular diagnostics.
The Pharma 2020 series
The Pharmaceutical industry's long successful strategy of placing big bets on a few molecules, promoting them heavily and turning them into blockbusters worked well for many years, but its R&D productivity has now plummeted and the environment’s changing. PwC believes that seven major trends are reshaping the marketplace:
Source of info:
http://www.pwc.com/gx/en/pharma-life-sciences/pharma2020/index.jhtml#
Women's Health Diagnostics Market PPT: Overview, Dynamics, Trends, Segmentati...IMARC Group
The global women's health diagnostics market size reached US$ 29.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 52.6 Billion by 2032, exhibiting a growth rate (CAGR) of 6.6% during 2024-2032.
More Info:- https://www.imarcgroup.com/womens-health-diagnostics-market
Companies, organizations, and research institutes that are committed to bettering the lives of living organisms fall under the umbrella term known as the life sciences industry. Pharmaceuticals, biotechnology, environmental sciences, biomedicine, nutraceuticals, neurology, cell biology, biophysics, and a lot of other subfields might be classified as some of the different subfields that fall under the umbrella of the life sciences business.
Global market for respiratory panel assaysMangeshFMI1
Respiratory infections with the increasing pollution have become a major cause of infectious diseases worldwide. These infectious diseases have become one of the causes of deaths in children and adults. With the growing urbanization and industrialization, pollution has also increased at an alarming rate and has led to an increase in bacterial and viral pathogens, which are the major the reasons of the respiratory infections. Respiratory diagnosis has become important with the rise of infections, also new technologies have been developed to identify the respiratory pathogens so as to control the infections timely. The growing number of infections are demanding more reliable and effective measures to curb respiratory infections. Early detection of respiratory diseases will minimize the damage caused due to secondary spread of infections.
As we understand more about the human body and how it functions and degrades, biotechnology will progress. This is only the beginning, but when new technology and procedures become accessible, certain themes will start to develop in biopharma trends.
Strand featured in CIO Review: Pharma and Life Science Special edition - July 2014
Strand Genomics Inc recognised by CIO Review as one among 20 most promising Tech solution providers to Pharma and Life science industry 2014
2014 Overview of significant trends in the life sciences (Biotechnology, Pharmaceutical, Device and Diagnostics) industry with Big Data in the Life Sciences featured articles.
Veterinary Diagnostics Market PPT 2024: Size, Growth, Demand and Forecast til...IMARC Group
The global veterinary diagnostics market size reached US$ 6.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 12.6 Billion by 2032, exhibiting a growth rate (CAGR) of 7.3% during 2024-2032.
More Info:- https://www.imarcgroup.com/veterinary-diagnostics-market
What You May Have Missed at AACC 2018 White Paper - Kalorama InformationBruce Carlson
Each year the American Association for Clinical Chemistry draws tens of thousands of lab professionals and in vitro diagnostic vendors to one place. Kalorama Information was there and noted major developments at the meeting in this White Paper. Major themes of scientific sessions, new products from lab and IVD vendors are included.
The American Association of Clinical Chemistry is the largest gathering of lab professionals. It's also a time and place for IVD suppliers to show off new products. This year in Philadelphia, there were new products on display and new trends in evident.
The United States might out-perform the IVD markets of many other nations in growth as well as size. Yet there are challenges. Will ACA-based changes be shortlived? This White Paper discusses them. Based on information from our United States IVD Market.
Roundup of This Year's AACC Meeting in AtlantaBruce Carlson
The American Association of Clinical Chemistry was held this year in Atlanta, GA. Kalorama was at the meeting and notes several developments, with a particular focus on point-of-care.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
1. The IVD Market: Current
Size and Expected Growth TrendDiagnostic laboratory technology has changed dramatically in the past few years, due to the publication
of the human genome project and advances in functional genomics, bioinformatics, miniaturization and
microelectronics. Not three years ago it would have been almost inconceivable to see research technologies
such as genome sequencing and mass spectroscopy play a pivotal role in improving lab medicine. Their
influence is felt in personalized medicine, inherited diseases, pathogen detection, antibiotic resistance testing,
blood banking and much more to come.
The world market for diagnostics is estimated at $54.2 billion in 2013 and is expected to grow 4% annually
to $64.3 billion by 2018. This includes all laboratory and hospital-based products, and OTC product sales.
Clinical lab medicine plays an integral role in healthcare and disease management. This phenomenon has seen
the major vendors of these technologies enter the IVD market. Life Technologies, Illumina, Affymetrix, Bruker
Daltonics, PerkinElmer/Caliper and others have all launched
clinical tests and test services.
Further the revolution in bioinformatics is allowing clinical and
traditional medical engineering to blend with components derived
from the telecommunications, information and computer sciences
industries. This opens new niche markets for POC test devices,
which will have a positive impact on diagnostic testing.
Health insurance giants Aetna, UnitedHealth and Kaiser in
collaboration with research organizations and IT companies are
working to make medicine really personalized. They are using Big
Data analytics engines that integrate the molecular information
(genomic, proteomic, metabolomic and others) from thousands of
patients that they insure with their demographic and disease
information to identify biomarkers linked to disease-driving
mechanisms. The long term goal is to develop markers that will
make personalized medicine very precise.
Lab-quality molecular tests and immunoassays at the point-of-care are on their way, but many of these tests
require some interpretation and consultation for appropriate disease management. To meet this demand
Smartphone apps have been launched just as fast as possible. The trend began with data analysis of blood
glucose monitoring to help people with diabetes improve management of their diabetes.
“…a time of global economic
instability and rising healthcare
costs.”
2. Now apps are available to help lab professionals consult with databases and experts worldwide. The
widespread availability of communication devices such as Apple’s iPAD and iPHONE and other android
phones and personal digital assistants are the most significant enablers of this phenomenon that will bring
quality diagnostics to people in remote areas of developing and developed countries.
However, these tests are being launched in Healthcare reform, the reformulation of reimbursement for the
newest and most valuable tests and the reorganization of the regulatory process for these tests in the U.S. have
created an environment of insecurity. The acute economic crisis in European countries has cut growth in the
IVD industry to 1% at best. Payers are cutting reimbursement schedules to the bare minimum to keep from
going broke. Japan has initiated its first pricing revision in ten years with an anticipated increase in payments.
On the supply side, labs are challenged to add new tests with little increase in financial and human
resources. For most labs it may even mean doing more with less.
There is also a lack of trained lab technologists, so there is a decreasing availability of human resources
needed to run the more complex new set of molecular and histological tests and immunoassays. Therefore there
has been a proliferation of test and lab automation tools launched that remove precious human resources from
mundane pre-analytical and sample tracking tasks to make time for more sophisticated ones. This phenomenon
was once thought to be the purview of core lab biochemistry and immunoassays but automation is becoming a
common feature hematology, blood banking, microbiology, and histology.
This emphasis on automation has created further
consolidation of laboratory testing to large core labs.
More and more assays in coagulation, infectious
diseases, proteins, diagetes and even HPV are
developed for automated clinical analyzers used in
the core lab. Systems for urinalysis, coagulation and
microbiology are ready to take their place along side
the hematology, chemistry and immunoassay
instruments – all located in a single core lab. In
larger labs they may be linked to a common track
line.
Getting information to care givers and patients is
now not an added plus, it is a prerequisite of all lab
operations. Thus the next 3-5 years will see an
intensification of the healthcare industry's emphasis
on informatics, wireless communications, data
networking and cost/effective healthcare delivery.
The reorganization of decentralized health care
delivery worldwide and patient-focused medicine are having an enormous impact on the role of medical devices
and diagnostic services in healthcare. Technological advancements, specifically those in device
Growth Rate by IVD Sector
3. miniaturization, data digitization, wireless communications and the Internet, form a technical synergy that will
permit IVD tests and devices to maintain a central role in disease management.
In the area of test economics, outcomes based disease management establishes guidelines and directives for
patient care. This is having a significant effect on the use of new tests, which have to prove their added value to
patient care. It also affects how many and which tests are
recommended and thus reimbursed for a specific disease
group. Health insurance companies such as Kaiser
Permanente, Aetna and UnitedHealth along with pharmacy
benefit organizations such as Medco are mining their
extensive databases to look for correlations between testing patterns and patient outcome. It is expected that
these would then be translated into test usage guideline.
For More Information, readers will want to consult Kalorama Information’s The Worldwide Market for
In Vitro Diagnostic Tests, 9th Edition. This updated report presents the trends, technologies, customer needs
and major suppliers with an eye on how they are shaping the IVD industry.
“…A number of world events
bode well for the future of
medical devices including IVDs.”
4. The Worldwide Market for In
Vitro Diagnostic Tests 9TH EDITION
The biennial edition of Kalorama’s comprehensive look at
the in vitro diagnostic market is coming soon.
Total Market Coverage
In nine best-selling editions, Shara Rosen has detailed the
market for in vitro diagnostic (IVD) testing, throughout the
world, in one complete volume.
Market numbers for business planning matched with a
discovery of the trends that are impacting the industry in
every IVD segment: Clinical Chemistry – Core Lab,
Molecular Diagnostics, Point of Care, Histology and
Cytology, Testing Services, IT in IVD, Test Services, CTCs,
Blood Banking Diagnostics, Microbiology and Virology,
Hematology and Immunoassays.
The report, The Worldwide Market for In Vitro Diagnostic
Tests, combines real industry knowledge with an
exhaustive review of the medical, business, and company
literature. Market sizes, forecasts and shares are provided,
as well as a geographic breakdown of the segments, where
possible.
Superior Trend Coverage
There are many sources for what happened in a market last year.
Kalorama Information’s unique report provides the reasons ‘why’
events happened. Changes in technology development,
regulatory and reimbursement issues, clinical care, and business
environments are discussed. Current market numbers are
presented for 2011, with projections given through 2016.
A Truly Global Resource
From the first edition, this report was designed as a global
resource in order to give market-watchers a true picture of the
industry. IVD is a worldwide business. While the US is a large
healthcare market, much of the dynamism, the growth, and also
competition is occurring in other areas.
Many of the most interesting opportunities for companies are occurring in
emerging markets. As part of its coverage, the report breaks down the entire
IVD market for North America, Europe (EU countries, incl. IVD market sizes
by country), Eastern Europe, South America, Asia (Japan, China and India) and Rest of World
5. IVD changes constantly.
This report keeps up with those
changes.
The need to know is what’s driving diagnostics. 6 Billion
Tests are performed each year. There are over 4,000 test
products. Just 2% of the costs of healthcare are spent on
testing, but 70% of clinical decisions are made using a
diagnostic test product. For infectious disease and cancer,
test makers with innovative products can expect
opportunities for new business.
Personalized medicine is finally on its way and not just for cancer patients. Why? Because pharma
companies are getting it – you can’t have a targeted therapeutic without an assay to select a potential
user. There has been a significant increase in pharma/Dx collaborations in the areas of neurological
disorders, autoimmune diseases and others.
For many years, we have heard about investment in emerging markets, the BRIC and others. In some
ways it was a lot of rhetoric – it is now a reality and all of the companies involved in emerging markets
have reported at least a 15%-20% increase in revenues there and in some cases more.
Mobile phones help us all find each other in big box stores, send Instagrams and generally keep in touch.
For healthcare providers – laboratory professionals, physicians and nurse practitioners – mobile phone
Apps are proving to be an invaluable tool to keep up to date, to
research disease guidelines and more.
Big data is all the buzz – let us not forget that data mining finds
correlations – many of which may have absolutely no significance
for the problem to be solved. It is only a beginning to finding real
answers that can improve patient care.
Is the liquid biopsy using either CTCs or cfDNA coming to routine
lab medicine? A sure sign of increased interest and uptake is
when test controls and standards are commercialized. In the past
few years several companies that market molecular test controls have increased their offerings in this
way.
The reimbursement conundrum continues – governments want better outcomes but also lower costs,
and developed countries are developing new reimbursement methods to counter these forms.
“the core lab of biochemistry,
immunoassays and hematology
still account for most IVD sales
but the last few years have
seen quite a bit of movement in
some areas.”
–Author, Shara Rosen
6. Extensive Coverage
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
Introduction – Doing more with less
Scope and Methodology
Size and Growth of the Market
Market Trends
2 INTRODUCTION
Background
Report Design
Lab Medicine Disciplines And Applications
Market Analysis of IVD Market Segments
The lure of IVD – new majors and entrants
Licenses and distribution agreements
Test Services
Top Suppliers and Niche players
Point of View
3 OVERVIEW OF GLOBAL IN VITRO DIAGNOSTIC
MARKETS
Background
Population and Disease Demographics, Worldwide
Chronic Diseases as a Market Driver
Cancer
Diabetes
Allergy
The BRIC Effect
World Segments of the IVD Market and IVD Market
Evolution
Specific Country Information
The United States of America – a world in flux
RUO/IUO Issues
The Patient Protection and Affordable Care Act
Accountable Care Organizations
LDT Oversight
Accent on Preventative Care
In Patient Bundling
Molecular test reimbursement
Japan
Europe – effects of austerity
IVD Directive Update
China
India
Brazil
Russia
4 TRENDS AND INNOVATION
Background
Looking to the East
Looking Past the Hospital ER
Telemedicine and Home Care Trends
Commercialization of Novel Tests
EMR Update
Wireless Connectivity and Healthcare Efficiencies
IVD Apps
5 POINT-OF-CARE TEST PLATFORMS
Overview of POC Tests
The Major POC Test Players
Market Analysis
Blood Glucose Monitoring
Blood Glucose Self Testing
Continuous Self Testing
Blood Glucose Testing by Professionals
Diabetes Testing – Glycated Hemoglobin
The Genetics of Diabetes
The Commercial Outlook for POC Tests
6 THE CORE LAB:
Core Lab Overview
Overview of Chemistry Tests
Market Analysis : Leading Suppliers and
Growth Potential
Lab-based Chemistries
Critical Care Analysis
Urinalysis
The Commercial Outlook for the Core Lab
7 IMMUNOASSAYS
Overview of Immunoassays
Market Analysis
Immunoassay Test Segments - Mature and
Emerging
Point-of-care OTC and Professional Use
The Commercial Outlook for Immunoassays
8MOLECULAR ASSAY PLATFORMS
Overview of Molecular Assays
Worldwide Opportunities for Molecular Tests
Molecular Test User Markets
Next generation Sequencing
Mass Spectroscopy
Molecular Technologies And Players
Market Analysis
Oncology
Inherited Diseases
Pharmacodiagnostics
Prenatal Chromosome Analysis
Tissue Typing
The Commercial Outlook for Molecular Tests
9 HEMATOLOGY
Overview of Hematology
Automation and IT
Digital Evolution
Decentralized Hematology Testing
Market Analysis : Leading Suppliers
The Commercial Outlook for Hematology Tests
7. 10 COAGULATION
Overview of Coagulation / Immunohematology
Tests
Special Topic
Genetics and Personalized Medicine
Warfarin
Plavix
Market Analysis
Lab-based Testing
Genetic markers of hypercoagulopathies
Decentralized Coagulation testing – Professional
Use
Decentralized Coagulation testing – OTC
Platelet Testing
Leading Suppliers
The Commercial Outlook for Coagulation Tests
11 MICROBIOLOGY AND VIROLOGY
Overview of Microbiology / Virology Tests
Special Topics
Antimicrobial Drug Resistance
Genome Sequencing and Mass Spectrometry
Sepsis Serology
Market Analysis
Supplies
Chromogenic Media
Microbial Identification and Antimicrobial
Sensitivity Tests
Liquid Microbiology
Blood Culture
Immunoassays – lab based
Immunoassays – rapid
Molecular Tests
The Commercial Outlook for Microbiology / Virology
Tests
12 BLOOD BANKING SERVICES
Overview of Blood Banking
Blood Management – are all these transfusions good
medicine
Blood Tracking
Chagas Disease
Platelet Safety
Market Analysis
Blood Grouping
Immunoassay Screens
Nucleic Acid Testing Continues to Grow
Leading Suppliers
The Commercial Outlook for Blood Banking
13 HISTOLOGY AND CYTOLOGY
Overview of Histology / Cytology
Special Topics
Companies expand with test services
Market Analysis
Histology/Cytology
Traditional Stains
Pap and HPV Tests
Immunochemistry and In Situ Hybridization
Pharmacodiagnostic Histology
Digital Imaging
Tissue Microarrays
Circulating Tumor Cells
Chromosome Analysis
Flow Cytometry
The Commercial Outlook for Histology and Cytology
Tests
14 COMPANY PROFILES – THE TOP TIER
15 COMPANY PROFILES – THE SECOND TIER
16 COMPANY PROFILES – NICHE PLAYERS
17 COMPANY PROFILES – BLOOD BANK
SPECIALISTS
18 COMPANY PROFILES – COAGULATION
SPECIALISTS
19 COMPANY PROFILES – DIABETES SPECIALISTS
20 COMPANY PROFILES – HEMATOLOGY
SPECIALISTS
20B – COMPANIES SPECIALIZING IN CIRCULATING
TUMOR CELLS
21 COMPANY PROFILES – HISTOLOGY SPECIALISTS
22 COMPANY PROFILES – IMMUNOASSAY
SPECIALISTS
23 COMPANY PROFILES – MICROBIOLOGY
SPECIALISTS MICRO.DOC
24 COMPANY PROFILES – MOLECULAR ASSAY
SPECIALISTS
25 COMPANY PROFILES – POINT-OF-CARE
SPECIALISTS
26 COMPANY PROFILES – TEST SERVICE PROVIDERS
27 COMPANY PROFILES – INFORMATION
TECHNOLOGY SPECIALISTS
28 COMPANY PROFILES – CORE LAB AND OTHER
COMPANIES